Overview of Clinical Research | <span style="font-family: arial, helvetica, sans-serif;"><span style="color:#000000;">Nolatrexed Dihydrochloride is a Thymidylate synthase inhibitor developed by Agouron Pharmaceuticals</span>. </span><span style="font-family: arial, helvetica, sans-serif; letter-spacing: 0.02em; orphans: 2; widows: 2; text-decoration: none; cursor: pointer; width: 85%;"><a class="profile-link" href="https://adisinsight.springer.com/trials/700263406" style="font-family: arial, helvetica, sans-serif; letter-spacing: 0.02em; orphans: 2; widows: 2; color: rgb(1, 118, 195); text-decoration: none; cursor: pointer; width: 85%;"><span style="color:#000000;">Nolatrexed or 5-fluorouracil in combination with cisplatin in patients with nasopharyngeal cancer</span></a></span><span style="font-family: arial, helvetica, sans-serif; letter-spacing: 0.02em; orphans: 2; widows: 2; color: rgb(0, 0, 0); text-decoration: none; cursor: pointer; width: 85%;"> was completed in 2015.</span>
|
Reference | <p>
<span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">1. <span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">Rafi, Imran, et al. "Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors." </span><i style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">Journal of clinical oncology</i><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;"> 16.3 (1998): 1131-1141.<br />
2.</span></span></span><span style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">Hy, Tu, and Chen Wm. "Synergistic anticancer effect of sodium phenylbutyrate combined with nolatrexed dihydrochloride in vitro." </span><i style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">Life Science Research</i><span style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;"> 7.4 (2003): 346-349.<br />
3.</span><span style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">Chen, S. Z., S. M. Wang, and J. R. Zhang. "Preparation of long-circulating nolatrexed dihydrochloride liposomes and its antitumor activity." </span><i style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">Journal of Southern Medical University</i><span style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;"> 28.3 (2008): 403-405.<br />
4.</span><span style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">LU, Hui-min, Wei-xia DU, and Ying-hua FU. "Inhibition Effect of Nolatrexed Dihydrochloride on Transplatation Tumors." </span><i style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">Journal of Preventive Medicine Information</i><span style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;"> 4 (2007): 8.</span></p>
|